Irbesartan Dawa

Irbesartan, the active ingredient in Irbesartan Dawa, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It treats hypertension in adults.

GNH USA supplies Irbesartan Dawa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan belongs to the angiotensin II receptor blocker class and is used to manage conditions related to the renin‑angiotensin system.

- Hypertension: lowers elevated blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows the progression of kidney damage in patients with type 2 diabetes. - Proteinuria associated with hypertension: decreases urinary protein excretion, helping preserve renal function.

Irbesartan is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach or urge to vomit. - Abdominal pain: discomfort in the stomach area. - Back pain: soreness in the lower back.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing. - Hyperkalemia: elevated potassium levels that can affect heart rhythm. - Acute kidney injury: sudden decline in renal function. - Hepatic injury: signs of liver damage such as jaundice. - Severe hypotension: markedly low blood pressure causing faintness. - Allergic rash: widespread skin eruption or hives.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal function monitoring: assess serum creatinine and eGFR regularly. - Electrolyte assessment: check potassium levels to detect hyperkalemia. - Hepatic impairment: use caution in patients with severe liver disease. - Pregnancy and lactation: avoid use during pregnancy; discontinue if pregnancy is confirmed. - Drug discontinuation: taper or stop under medical supervision to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of dangerous hyperkalemia. - Aliskiren (in diabetic patients): may increase renal adverse events. - ACE inhibitors: combined use can cause excessive potassium rise and renal dysfunction.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and impair kidney function. - Lithium: increased lithium levels, risk of toxicity. - Cyclosporine or tacrolimus: may elevate serum creatinine. - Diuretics: may enhance hypotensive effect; monitor blood pressure.